宏川智慧(002930.SZ):與誠志股份簽署戰略合作框架協議書
格隆匯 8 月 23日丨宏川智慧(002930.SZ)公佈,公司與誠志股份有限公司(“誠志股份”)於2020年8月21日在東莞市簽署了《戰略合作框架協議書》,約定以促進雙方友好協作、可持續發展為目標,加強雙方在各自業務領域的優勢互補和全方位合作,實現強強聯合。
雙方作為在深圳證券交易所上市的上市公司,依託雙方業務覆蓋廣、產業鏈延伸長等優勢和特點,本着互惠互利、共同發展的原則,充分發揮上市公司優勢進行資本合作,在資本市場符合預期,滿足法律法規要求及監管規則允許的前提下,雙方有意願進一步探討資本領域的合作事宜,包括認購/參與非公開發行股票、可轉債、公司債券、併購基金等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.